Geode Capital Management
TARO

Geode Capital Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Geode Capital Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-93,934
Closed -$3.98M – 4645
2024
Q1 		$3.98M Buy
93,934
+1,121
+1% +$47.2K ﹤0.01% 2823
2023
Q4 		$3.88M Buy
92,813
+4,340
+5% +$160K ﹤0.01% 2832
2023
Q3 		$3.34M Buy
88,473
+5,937
+7% +$223K ﹤0.01% 2848
2023
Q2 		$3.13M Buy
+82,536
New +$2.59M ﹤0.01% 2946
2020
Q1 		– Sell
-7,650
Closed -$671K – 4187
2019
Q4 		$671K Sell
7,650
-10,786
-59% -$910K ﹤0.01% 3414
2019
Q3 		$1.39M Buy
18,436
+2,743
+17% +$223K ﹤0.01% 3111
2019
Q2 		$1.34M Buy
15,693
+4,586
+41% +$454K ﹤0.01% 3133
2019
Q1 		$1.2M Buy
11,107
+3,852
+53% +$384K ﹤0.01% 3086
2018
Q4 		$613K Buy
7,255
+4,018
+124% +$387K ﹤0.01% 3296
2018
Q3 		$318K Buy
3,237
+398
+14% +$43.1K ﹤0.01% 3606
2018
Q2 		$327K Buy
2,839
+347
+14% +$38.1K ﹤0.01% 3567
2018
Q1 		$245K Sell
2,492
-2,406
-49% -$244K ﹤0.01% 3622
2017
Q4 		$511K Sell
4,898
-30,739
-86% -$3.38M ﹤0.01% 3353
2017
Q3 		$4M Buy
35,637
+398
+1% +$43.3K ﹤0.01% 2340
2017
Q2 		$3.94M Buy
35,239
+4,160
+13% +$470K ﹤0.01% 2305
2017
Q1 		$3.62M Buy
31,079
+2,295
+8% +$254K ﹤0.01% 2302
2016
Q4 		$3.03M Sell
28,784
-603
-2% -$63.2K ﹤0.01% 2387
2016
Q3 		$3.24M Buy
29,387
+3,272
+13% +$433K ﹤0.01% 2246
2016
Q2 		$3.79M Buy
26,115
+12,298
+89% +$1.74M ﹤0.01% 2098
2016
Q1 		$1.97M Buy
13,817
+1,008
+8% +$143K ﹤0.01% 2469
2015
Q4 		$1.97M Buy
+12,809
New +$1.87M ﹤0.01% 2500
2015
Q3 		– Sell
-2,463
Closed -$353K – 4138
2015
Q2 		$353K Sell
2,463
-541
-18% -$77.2K ﹤0.01% 3357
2015
Q1 		$423K Sell
3,004
-5,050
-63% -$777K ﹤0.01% 3259
2014
Q4 		$1.19M Buy
8,054
+5,320
+195% +$782K ﹤0.01% 2738
2014
Q3 		$420K Buy
+2,734
New +$412K ﹤0.01% 3243

Other funds holding TARO

KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $1.65B AUM 25.75% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Geode Capital Management's TARO Position: Q2 2024 in Review

Geode Capital Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 93,934 shares — an estimated $3.98M sold.

Geode Capital Management first reported a position in TARO in Q3 2014 and held it in 25 quarters. The position peaked at $4M in Q3 2017. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • Geode Capital Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 93,934 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $3.98M.
  • Geode Capital Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2014 and held it in 25 quarters.
  • Geode Capital Management's Taro Pharmaceutical Industries Ltd. position peaked at $4M in Q3 2017.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.